Index. Note: Page numbers of article titles are in boldface type.

Transcription

1 Note: Page numbers of article titles are in boldface type. A Abatacept for eye diseases, 817 for juvenile dermatomyositis, 894 for juvenile idiopathic arthritis, 756, Acne, in SAPHO syndrome, 745 Activities Scale for Kids, 929 Adalimumab for eye diseases, for juvenile idiopathic arthritis, Adrenocorticotropic hormone gel, for juvenile dermatomyositis, Aicardi-Goutieres syndrome, 708 Alemtuzumab for eye diseases, 818 for juvenile dermatomyositis, 895 American Heart Association, Kawasaki disease guidelines of, 862 American Recovery and Reinvestment Act of 2009, 922 American Scleroderma Stem Cell vs. Immune Suppression (ASSIST) trial, 917 American Uveitis Society, 814 Amyloidosis, in familial Mediterranean fever, 719 Amyopathic dermatomyositis, 879 Anakinra for cryopyrinopathies, 717 for juvenile dermatomyositis, 894 for juvenile idiopathic arthritis, 756, Anemia, in Majeed syndrome, 742 Aneurysms in Kawasaki disease, in Takayasu arteritis, Antibodies, in juvenile idiopathic inflammatory myopathies, Anticoagulation, for Kawasaki disease, Antineutrophil cytoplasmic autoantibodies, in vasculitis, Aorta, Takayasu arteritis of, Aphthous lesions, in Behçet syndrome, 808 Apremilast, for spondyloarthritis, 781 ARChiVe registry, Arteritis, Takayasu, Arthritis. See also Spondyloarthritis. juvenile idiopathic, pediatric granulomatous, , 711, psoriatic, pyogenic sterile, 706, Rheum Dis Clin N Am 39 (2013) rheumatic.theclinics.com X/13/$ see front matter ª 2013 Elsevier Inc. All rights reserved.

2 936 Aspirin for Kawasaki disease, Assessment of Spondyloarthritis International Society, 769 ASSIST (American Scleroderma Stem Cell vs. Immune Suppression) trial, 917 ASTIS (Autologous Stem Cell Transplantation International Scleroderma) trial, Atherosclerosis, in spondyloarthropathy, 778 Autoantibodies, in juvenile idiopathic inflammatory myopathies, Autoinflammatory diseases. See Pediatric autoinflammatory diseases. Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, Axial arthritis, in spondyloarthropathy, Azathioprine for Behçet syndrome, 810 for juvenile dermatomyositis, 890 for lupus nephritis, for Vogt-Koyanagi-Harada syndrome, Azithromycin, for chronic nonbacterial osteomyelitis, 737 B B227PD, for eye diseases, 819 Back pain, inflammatory, Behçet syndrome, 803, Bevacizumab, for eye diseases, 818 Biologics. See also individual agents. for eye diseases, for juvenile dermatomyositis, for juvenile idiopathic arthritis, Biomarkers for lupus nephritis, for scleroderma, for Takayasu arteritis, 867 Biopsy for chronic nonbacterial osteomyelitis, 740 for lupus nephritis, for scleroderma, 911, 913 Bisphosphonates, for chronic nonbacterial osteomyelitis, Blau syndrome (pediatric granulomatous arthritis), 707, 711, Blood-retinal barrier, in eye diseases, 804 Bone diseases, cherubism, 736, chronic nonbacterial osteomyelitis, deficiency of interleukin-1 receptor antagonist, 736, genetic, juvenile mandibular chronic osteomyelitis, 745 Majeed syndrome, 702, 705, , , 721, 736, overview of, SAPHO syndrome, 736, 745 Bone marrow transplantation, in scleroderma,

3 937 Bone scans, in chronic nonbacterial osteomyelitis, 739 Bruits, in Takayasu arteritis, 866 C CADM-140, autoantibodies to, 885, 887 Calcineurin inhibitors, for eye diseases, 813 Calprotectin, in spondyloarthropathy, 778 CAMPS (CARD14-mediated psoriasis), 706, 711, Canadian Alliance of Pediatric Rheumatology Investigations (CAPRI), 924 Canakinumab for cryopyrinopathies, 717 for eye diseases, 816 for juvenile idiopathic arthritis, 756, Cancer-associated myositis, 880, 883 CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature), 702, 705, Capillaroscopy, for scleroderma, 914 CAPS. See Cryopyrinopathies (cryopyrin-associated periodic syndromes, CAPS). CARD14-mediated psoriasis (CAMPS), 706, 711, , 771, 885 Cardiac catheterization, for Kawasaki disease, 861 Cardiac involvement, in Kawasaki disease, Cardiopulmonary function test, for scleroderma, 915 CARRA (Childhood Arthritis and Rheumatology Research Alliance), Cataract, in Behçet syndrome, Ceruloplasmin, in lupus nephritis, 842 Chemokines, in lupus nephritis, Cherubism, 736, Child Health Assessment Questionnaire, 885, 929 Child Health Questionnaire, 929 Childhood Arthritis and Rheumatology Research Alliance (CARRA), 771, 885, Childhood autoinflammatory diseases. See Pediatric autoinflammatory diseases. Childhood Myositis Assessment Scale, 885 Chlorambucil, for Vogt-Koyanagi-Harada syndrome, Choroiditis, in Vogt-Koyanagi-Harada syndrome, Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), 702, 705, Chronic infantile neurologic cutaneous and articular (CINCA) syndrome (NOMID), , 709, Chronic nonbacterial osteomyelitis, Chronic recurrent multifocal osteomyelitis, Churg-Strauss syndrome, CINCA (chronic infantile neurologic cutaneous and articular syndrome, NOMID), , 709, Clopidogrel, for Kawasaki disease, 862 Cogan syndrome, 803, Colchicine, for familial Mediterranean fever, 719 Comparative effectiveness research. See Outcomes research. Complement, in lupus nephritis, 838, 842 Composite index, for scleroderma, 911

4 938 Computed tomography angiography, for Takayasu arteritis, Congenital dyserythropoietic anemia, in Majeed syndrome, 742 Core Set of Variables, for clinical trials, 927 Coronary artery disease, in Kawasaki disease, Corticosteroids for Behçet syndrome, 810 for Cogan syndrome, 812 for eye diseases, for juvenile dermatomyositis, 890, 895 for juvenile idiopathic arthritis, 754 for Kawasaki disease, for PRAAS, 724 for scleroderma, 916 for tubulointerstitial nephritis and uveitis syndrome, 803, 808 for Vogt-Koyanagi-Harada syndrome, C-reactive protein in Kawasaki disease, 862 in Takayasu arteritis, Cryopyrinopathies (cryopyrin-associated periodic syndromes, CAPS), clinical features of, pathogenesis of, treatment of, 717 CXC chemokines and receptors, in lupus nephritis, Cyclophosphamide for Cogan syndrome, 812 for juvenile dermatomyositis, 888, 890, 892, 895 for Kawasaki disease, 863 for lupus nephritis, for Vogt-Koyanagi-Harada syndrome, Cyclosporine for eye diseases, 813 for juvenile dermatomyositis, 888, for Kawasaki disease, 863 for Vogt-Koyanagi-Harada syndrome, Cytokines in chronic nonbacterial osteomyelitis, in eye diseases, 804 in Kawasaki disease, 858 in monogenic autoinflammatory diseases, 709, 713 in Takayasu arteritis, 865 D Deficiency of IL-36 receptor antagonist (DITRA), 702, 706, 711, Deficiency of interleukin-1 receptor antagonist (DIRA), 702, 705, , 721, 736, Dermatomyositis, juvenile. See Juvenile dermatomyositis. Dermatomyositis sine myositis, 882 Dermatoses, in Majeed syndrome, 742

5 939 Diffuse mandibular chronic osteomyelitis, 745 DIRA (deficiency of interleukin-1 receptor antagonist), 702, 705, , 721, 736, DISABKIDS assessment tool, 929 Disease-modifying antirheumatic drugs for eye diseases, for juvenile idiopathic arthritis, for spondyloarthritis, 780 for Vogt-Koyanagi-Harada syndrome, DITRA (deficiency of IL-36 receptor antagonist), 702, 706, 711, Dolorimetry, for spondyloarthropathy, Doppler studies, for scleroderma, 909 Durometer, for sclerosis measurement, Dutch National Biologics Register, 923 E Echocardiography, for Kawasaki disease, 861 Electrocardiography, for Kawasaki disease, 861 Enthesitis, in spondyloarthropathy, Enthesitis-related arthritis, 752 Eosinophilic granulomatosis with polyangiitis, Eosinophilic myositis, 881 ERAP1 gene mutations, in spondyloarthritis, Erythrocyte sedimentation rate, in Takayasu arteritis, ESBAQ-105, for eye diseases, 819 Etanercept for eye diseases, for juvenile dermatomyositis, 888, 894 for juvenile idiopathic arthritis, Euro Lupus Regimen, European League Against Rheumatism, 906 European Spondyloarthropathy Study Group, 769 Everolimus, for eye diseases, Exercise, for juvenile dermatomyositis, 896 Exercise testing, for scleroderma, 915 Eye diseases, F FABER test, 777 Familial cold autoinflammatory syndrome (FCAS), 702, 709, Familial Mediterranean fever (FMF), 702, 704, 710, 713 FCAS (familial cold autoinflammatory syndrome), 702, 709, Federal Coordinating Council for Comparative Effectiveness Research, 922 FMF (familial Mediterranean fever), 702, 704, 710, 713 Focal myositis, 880, 883 G Gastrointestinal inflammation, in spondyloarthropathy, 778 Generic Core Scales, for assessment, 929

6 940 Genome-wide association studies, in spondyloarthritis, 779 German Etanercept Registry, 923 Glaucoma, in Behçet syndrome, Glomerular filtration rate, in lupus nephritis, 837 Glove finger, in Kawasaki disease, 858 Glucocorticoids. See Corticosteroids. Golimumab for eye diseases, 815 for spondyloarthritis, 781 Graft-versus-host myositis, 881 Granulomatous disease, Granulomatous myositis, 881 Granulomatous panuveitis, in Vogt-Koyanagi-Harada syndrome, H Headache, in Takayasu arteritis, 866 Health Utility, 923 Hearing loss in Cogan syndrome, in cryopyrinopathies, Henoch-Schoenlein purpura, 856 Heparin, for Kawasaki disease, Hepcidin, in lupus nephritis, HIDS (hyperimmunoglobulinemia D with periodic fever syndrome), 702, 704, , , Human leukocyte antigens in inflammatory eye diseases, , 806 in spondyloarthopathy, in Takayasu arteritis, 865 Humoral immunity, in Takayasu arteritis, 865 Hydroxychloroquine for juvenile dermatomyositis, 890, 895 for lupus nephritis, Hyperimmunoglobulinemia D with periodic fever syndrome (HIDS), 702, 704, , , Hypertension, in Takayasu arteritis, 866 Hypomyopathic dermatomyositis, 879, I ILIRN gene mutations, in deficiency of interleukin-1 receptor antagonist, Immune-mediated necrotizing myopathy, 881 Immunoglobulin, intravenous for juvenile dermatomyositis, 888, 890, for Kawasaki disease, Immunosuppressants for Behçet syndrome, 810 for juvenile idiopathic arthritis, 754 for lupus nephritis,

7 Inclusion body myositis, 879 Inflammasomes, in monogenic autoinflammatory diseases, , Inflammatory back pain, Inflammatory bowel disease, early onset, 707, 711, Inflammatory diseases, pediatric. See Pediatric autoinflammatory diseases. Inflammatory eye diseases, See also Uveitis. Behçet syndrome, 803, Cogan syndrome, 803, outcomes of, 819 pars planitis, 803, spectrum of, treatment of, tubulointerstitial nephritis and uveitis syndrome, 803, 808 Vogt-Koyanagi-Harada syndrome, 803, Inflammatory myopathies. See Juvenile idiopathic inflammatory myopathies. Infliximab for Behçet syndrome, 811 for eye diseases, 816 for juvenile dermatomyositis, 888, 894 for juvenile idiopathic arthritis, for Kawasaki disease, 863 for pars planitis, 808 for Vogt-Koyanagi-Harada syndrome, 807 Infrared thermography, for scleroderma, 915 Interferon-a, for Behçet syndrome, Interleukin(s) in eye diseases, 804 in Takayasu arteritis, 867 Interleukin-1 inhibitors for eye diseases, 816 for juvenile idiopathic arthritis, Interleukin-1 mediated autoinflammatory diseases, clinical features of, pathogenesis of, 709, treatment of, Interleukin-2 inhibitors, for eye diseases, Interleukin-6 inhibitors, for eye diseases, 817 Interleukin-10, in chronic nonbacterial osteomyelitis, Interleukin-17 inhibitors, for eye diseases, 817 Interleukin-23 defects of, in spondyloarthritis, in Vogt-Koyanagi-Harada syndrome, 807 Interleukin-36 deficiency, 702, 706, 711, International League of Associations for Rheumatology classification, of juvenile idiopathic arthritis, International Myositis Assessment and Clinical Studies Group, 885 International Society of Nephrology/Renal Pathology Society, Interstitial keratitis, in Cogan syndrome, Ischemia, in Takayasu arteritis,

8 942 J JADAS (Juvenile Arthritis Disease Activity Score), 927 Jaw, bony changes of, in cherubism, JIA. See Juvenile idiopathic arthritis. Jo-1, antibodies to, 884, 886 Juvenile Arthritis Disease Activity Score (JADAS), 927 Juvenile Arthritis Functionality Scale, 929 Juvenile Arthritis Quality of Life Questionnaire, 929 Juvenile autoinflammatory diseases. See Pediatric autoinflammatory diseases. Juvenile dermatomyositis, 878, 885, Juvenile idiopathic arthritis, classification of, 768 clinical trials of, subtypes of, treatment of, biologics, disease-modifying antirheumatic drugs, nonsteroidal anti-inflammatory drugs, 754 uveitis in, , 805 Juvenile idiopathic inflammatory myopathies, classification of clinicopathologic, serologic, dermatomyositis, 878, Juvenile mandibular chronic osteomyelitis, 745 Juvenile polymyositis, 882 Juvenile Scleroderma Inception Cohort Project, 906 Juvenile systemic scleroderma and juvenile localized scleroderma, biomarkers for, classification of, diagnosis of, 906 outcome measures for, 906, 908 prevalence of, 905 skin involvement in, treatment of, K Kawasaki disease, clinical presentation of, complications of, 864 criteria for, definition of, 858 diagnosis of, differential diagnosis of, 862 evolution of, 864 pathogenesis of, 858 prognosis for, 864 treatment of, Keratinocyte dysfunction, in monogenic autoinflammatory diseases, 709 Keratitis, interstitial, in Cogan syndrome,

9 943 Kidney, biopsy of, for lupus nephritis, Ku, autoantibodies to, 887 L La, autoantibodies to, 887 Laser color Doppler, for scleroderma, Laser-capture microdissection, for lupus nephritis, 839 Leflunomide for Cogan syndrome, 812 for juvenile idiopathic arthritis, 755 LIPIN2 gene mutations, in Majeed syndrome, 743 Lipin defects, in Majeed syndrome, 715, 717 Lipocalin-type prostaglandin D synthase, 842 Lipopolysaccharides, in chronic nonbacterial osteomyelitis, 737 Localized scleroderma. See Juvenile systemic scleroderma and juvenile localized scleroderma. Localized Scleroderma Skin Severity, Lupus nephritis, biomarkers for, classification of, course of, 834 criteria for, 834 diagnosis of, economic impact of, 834 epidemiology of, 834 monitoring of, outcome of, 836 risk factors for, 836 traditional measures of, treatment of, Lymphadenopathy, in Kawasaki disease, 859 M Macrophagic myofasciitis, 881, 883 Macular edema, in Behçet syndrome, Magnetic resonance angiography, for Takayasu arteritis, Magnetic resonance imaging for spondyloarthropathy, in chronic nonbacterial osteomyelitis, 739 Majeed syndrome, 702, 705, , , 721, 736, Mandible bony changes of, in cherubism, juvenile mandibular chronic osteomyelitis of, 745 Maxilla, bony changes of, in cherubism, Methotrexate for Cogan syndrome, 812 for eye diseases, for juvenile dermatomyositis, 888, for juvenile idiopathic arthritis, 754

10 944 Methotrexate (continued) for pars planitis, 808 for scleroderma, 916 for spondyloarthritis, for Vogt-Koyanagi-Harada syndrome, Methyl prednisolone, for eye diseases, 818 Methylprednisolone, for juvenile dermatomyositis, 888, 890 Mevalonate kinase deficiency, 702, 704, , , Mi-2, autoantibodies to, 886 Microarray analysis, for lupus nephritis, 838 Microscopic polyangiitis, MJ, autoantibodies to, 884, 886 Modified Rodman Skin Score, 908 Modified Stoke AS Spine Score, 781 Monoclonal antibodies, for juvenile idiopathic arthritis, Monocyte chemoattractant protein-1, in lupus nephritis, Monogenic autoinflammatory diseases, See also individual diseases. clinical features of, definition of, 702 demographics of, genetics of, interleukin-1 mediated, non-interleukin-1 mediated, overview of, pathogenesis of, Morphea, 908 Muckle-Wells syndrome (MWS), , 709, Mutton-fat keratic precipitates, in Vogt-Koyanagi-Harada syndrome, MWS (Muckle-Wells syndrome), , 709, Mycophenolate mofetil for Cogan syndrome, 812 for eye diseases, for juvenile dermatomyositis, 892 for lupus nephritis, for scleroderma, 916 for Vogt-Koyanagi-Harada syndrome, Myocarditis, in Kawasaki disease, Myopathies, inflammatory. See Juvenile idiopathic inflammatory myopathies. Myositis-associated autoantibodies, in juvenile idiopathic inflammatory myopathies, Myositis-specific autoantibodies, in juvenile idiopathic inflammatory myopathies, N National Institutes of Health Histology Score, for lupus nephritis, Neonatal-onset multisystem inflammatory disease (NOMID), , 709, Nephritis in tubulointerstitial nephritis and uveitis syndrome, 803, 808 lupus,

11 945 Neurologic disorders, in Takayasu arteritis, 866 Neutrophil gelatinase-associated lipocalin, in lupus nephritis, 838, 841 NOMID (Neonatal-onset multisystem inflammatory disease), , 709, Nonsteroidal anti-inflammatory drugs for chronic nonbacterial osteomyelitis, 740 for juvenile idiopathic arthritis, 754 for SAPHO syndrome, 745 O Ocular/optical coherence tomography, 805, 810, 910 Oligoarticular juvenile idiopathic arthritis, Optiquel, for eye diseases, 819 Orbital myositis, 880 Orosomucoid, in lupus nephritis, 842 Osteitis, in deficiency of interleukin-1 receptor antagonist, Osteomyelitis, chronic nonbacterial, Outcome in AS International Study cohort, 781 Outcomes research, assessment methods for, definition of, 922 networks for improvement in, overview of, patient-reported outcome assessment in, , registries in, Overlap myositis, 879, 882 P p28/p40 cytokine, for eye diseases, 818 p155/140, autoantibodies to, 884, 886 Pamidronate for chronic nonbacterial osteomyelitis, for SAPHO syndrome, 745 PAPA (pyogenic sterile arthritis, pyoderma gangrenosum, and acne) syndrome, 706, 722 Pars planitis, 803, Patient Protection and Affordable Care Act, 922 Patient Reported Outcomes Measurement Information System (PROMIS), 929 Patient-Centered Outcomes Research Trust Fund, 922 Patient-reported outcome assessment, in outcomes research, , Patrick test, 777 Pattern recognition receptors, defects of, 708 Pediatric autoinflammatory diseases bone, eye, inflammatory bowel disease, juvenile idiopathic arteritis, juvenile idiopathic inflammatory myopathies, juvenile spondyloarthritis, lupus nephritis, monogenic,

12 946 Pediatric (continued ) outcomes of, scleroderma, vasculitis, Pediatric granulomatous arthritis (PGA), , 711, Pediatric Quality of Life Inventory, 929 Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN), , 928 Pediatric Rheumatology Collaborative Study Group, 923 Pediatric Rheumatology European Society, 906 Pediatric Rheumatology International Trials Organization (PRINTO), 885, 923 Pediatric Rheumatology Quality of Life Scale, 929 Periodic fever syndromes, See also individual disorders. Periostitis, in deficiency of interleukin-1 receptor antagonist, Peripheral arthritis, in spondyloarthropathy, PGA (pediatric granulomatous arthritis), 707, 711, PharmaChild registry, 923 Physical fitness test, for scleroderma, 915 Physician Global Assessment, for scleroderma, 911 Pimecrolimus, for juvenile dermatomyositis, 895 PM-Scl, autoantibodies to, 885, 887 Polyarteritis, nodosa, Polyarticular juvenile idiopathic arthritis, 752 Polymyositis, 879 Positron emission tomography, for Takayasu arteritis, 868 PRAAS (Proteasome-associated autoinflammatory syndromes), 702, 705, PR-COIN (Pediatric Rheumatology Care and Outcomes Improvement Network), , 928 Prednisolone for Kawasaki disease, 863 Prednisone for juvenile dermatomyositis, 888, 891 for Vogt-Koyanagi-Harada syndrome, 806 PRINTO (Pediatric Rheumatology International Trials Organization), 885, 923 Proliferative myositis, 881 PROMIS (Patient Reported Outcomes Measurement Information System), 929 Pronatriuretic hormone, in scleroderma, Propionibacterium acnes, in chronic nonbacterial osteomyelitis, 737 Proteasome-associated autoinflammatory syndromes (PRAAS), 702, 705, Protein signature, urine, in lupus nephritis, 842 Proteinuria, in lupus nephritis, 836 Proteomics, for lupus nephritis, 839 Psoriasis CARD14-mediated (CAMPS), 706, 711, in SAPHO syndrome, 745 Psoriatic arthritis, Psoriatic juvenile idiopathic arthritis, 752 PSTPIP gene mutations, in chronic nonbacterial osteomyelitis, Pulse, absence of, in Takayasu arteritis, 866

13 947 Pustulosis in deficiency of interleukin-1 receptor antagonist, in SAPHO syndrome, 745 Pyogenic sterile arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome, 706, Q Quality of My Life Questionnaire, 929 R Radiography, in chronic nonbacterial osteomyelitis, 739 Ranibizumab, for eye diseases, 818 Rash in deficiency of interleukin-1 receptor antagonist, in juvenile idiopathic inflammatory myopathies, 878 in Kawasaki disease, 858 Retinal vasculitis, in Behçet syndrome, Retinopathy, in Takayasu arteritis, 866 Rheumatoid factor, in juvenile idiopathic arthritis, 752 Rheumatology Clinical Registry of the American College of Rheumatology, 926 Rilonacept for cryopyrinopathies, 717 for juvenile idiopathic arthritis, Rituximab for eye diseases, for juvenile dermatomyositis, 888, 893 for juvenile idiopathic arthritis, 755, for Kawasaki disease, 863 for lupus nephritis, 845 Ro, autoantibodies to, 885 Rodman Skin Score, Modified, 908 S Sacroiliitis, , 780 SAE, autoantibodies to, 887 SAPHO syndrome, 736, 745 Sarcoidosis (pediatric granulomatous arthritis), 707, 711, Schober test, 777 Scleroderma. See Juvenile systemic scleroderma and juvenile localized scleroderma. SCOT (Scleroderma Cyclophosphamide or Transplantation) trial, 917 Secukinumab for eye diseases, 817 for spondyloarthritis, 781 SH3BP2 gene mutations, in cherubism, Sifalimumab, for juvenile dermatomyositis, 894 Sirolimus, for eye diseases, minute walk test, for scleroderma, 915 Slit-lamp examination for Behçet syndrome, 898

14 948 Slit-lamp (continued) for Vogt-Koyanagi-Harada syndrome, 806 Sm, autoantibodies to, 887 Snowbanking and snowball formation, in pars planitis, Spondyloarthritis, juvenile, classification of, clinical features of, extra-articular manifestations of, genetic susceptibility in, pathogenesis of, treatment of, SRP, autoantibodies to, Statins, for Kawasaki disease, 863 Stem cell transplantation for juvenile dermatomyositis, 895 in scleroderma, Strawberry tongue, in Kawasaki disease, 859 Sulfasalazine for juvenile idiopathic arthritis, 755 for spondyloarthritis, Synthetase, autoantibodies to, 882, 884, 886 Systemic lupus erythematosus, nephritis in. See Lupus nephritis. Systemic scleroderma. See Juvenile systemic scleroderma and juvenile localized scleroderma. T T cells, in Takayasu arteritis, 865 Tacrolimus for eye diseases, 813 for juvenile dermatomyositis, 888, 892, 895 Takayasu arteritis, clinical presentation of, criteria for, 868 diagnosis of, differential diagnosis of, 869 evolution of, 870 imaging for, pathogenesis of, 865 prognosis for, 870 treatment of, Temporomandibular joint involvement, in scleroderma, 913 Thermography for scleroderma, , 915 Tocilizumab for eye diseases, 817 for juvenile dermatomyositis, 894 for juvenile idiopathic arthritis, 756, 761 Transferrin, in lupus nephritis, 842 TRAPS (tumor necrosis factor receptor-associated periodic syndrome), 704, , , 720

15 949 Triamcinolone for Behçet syndrome, 810 for juvenile idiopathic arthritis, 754 Tuberculosis, Takayasu arteritis and, 865 Tubulointerstitial nephritis and uveitis syndrome, 803, 808 Tumor necrosis factor antagonists, for chronic nonbacterial osteomyelitis, Tumor necrosis factor inhibitors for eye diseases, for juvenile idiopathic arthritis, Tumor necrosis factor receptor-associated periodic syndrome (TRAPS), 704, , , 720 TWEAK (tumor necrosis factor-like weak inducer of apoptosis), /100, autoantibodies to, 885 U U1-RNP, autoantibodies to, 885, 887 Ulcers, in Behçet syndrome, 808 Ultrasonography for scleroderma, 909 for spondyloarthropathy, Ultraviolet radiation, for juvenile dermatomyositis, 895 Urine sediment, in lupus nephritis, 836 Urine tests, for lupus nephritis, Uveitis clinical presentation of, diagnosis of, diseases associated with, 802, epidemiology of, 802 in scleroderma, 913 in spondyloarthropathy, outcomes of, 819 pathogenesis of, 804 treatment of, types of, 802 V Vascular endothelial growth factor inhibitors for eye diseases, 818 for lupus nephritis, Vasculitis, clinical features of, 856 forms of, in Cogan syndrome, in Kawasaki disease, in scleroderma, 913 in Takayasu arteritis, pathogenesis of, Vision loss in Behçet syndrome, in eye diseases,

16 950 Vitreous inflammation, in pars planitis, Vogt-Koyanagi-Harada syndrome, 803, W Warfarin, for Kawasaki disease, Weakness, in juvenile idiopathic inflammatory myopathies, Wolf-Hirschhorn syndrome, 745